Oops, something went wrong
VRTX is a biotechnology company focused on treatments for cystic fibrosis, influenza, bacterial infections, rheumatoid arthritis, cancer, inflammatory bowel disease, and neurological disorders including pain and multiple sclerosis. VRTX's second-quarter fiscal 2027 report showed $3.3 billion in quarterly revenue (a 12% year-over-year gain), non-GAAP per-share earnings of $4.73 (a 5% jump), roughly $13.6 billion in cash and investments, and increased full-year revenue guidance to a top end of $13.2 billion.
It's no wonder VRTX shares are up 13% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the forward picture of the stock.
Institutional volumes reveal plenty. In 2026, VRTX has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in VRTX shares. They reflect our proprietary inflow signal, pushing the stock higher:
